FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386505453> ?p ?o ?g. }

• W4386505453 abstract "Emerging data suggest that direct oral anticoagulants may be a suitable choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high-quality trials in CVT is challenging as it is a rare disease with low rates of adverse outcomes such as major bleeding and functional dependence. To facilitate the design of future CVT trials, SECRET (Study of Rivaroxaban for Cerebral Venous Thrombosis) assessed (1) the feasibility of recruitment, (2) the safety of rivaroxaban compared with standard-of-care anticoagulation, and (3) patient-centered functional outcomes.This was a phase II, prospective, open-label blinded-end point 1:1 randomized trial conducted at 12 Canadian centers. Participants were aged ≥18 years, within 14 days of a new diagnosis of symptomatic CVT, and suitable for oral anticoagulation; they were randomized to receive rivaroxaban 20 mg daily, or standard-of-care anticoagulation (warfarin, target international normalized ratio, 2.0-3.0, or low-molecular-weight heparin) for 180 days, with optional extension up to 365 days. Primary outcomes were annual rate of recruitment (feasibility); and a composite of symptomatic intracranial hemorrhage, major extracranial hemorrhage, or mortality at 180 days (safety). Secondary outcomes included recurrent venous thromboembolism, recanalization, clinically relevant nonmajor bleeding, and functional and patient-reported outcomes (modified Rankin Scale, quality of life, headache, mood, fatigue, and cognition) at days 180 and 365.Fifty-five participants were randomized. The rate of recruitment was 21.3 participants/year; 57% of eligible candidates consented. Median age was 48.0 years (interquartile range, 38.5-73.2); 66% were female. There was 1 primary event (symptomatic intracranial hemorrhage), 2 clinically relevant nonmajor bleeding events, and 1 recurrent CVT by day 180, all in the rivaroxaban group. All participants in both arms had at least partial recanalization by day 180. At enrollment, both groups on average reported reduced quality of life, low mood, fatigue, and headache with impaired cognitive performance. All metrics improved markedly by day 180.Recruitment targets were reached, but many eligible participants declined randomization. There were numerically more bleeding events in patients taking rivaroxaban compared with control, but rates of bleeding and recurrent venous thromboembolism were low overall and in keeping with previous studies. Participants had symptoms affecting their well-being at enrollment but improved over time.URL: https://www.gov; Unique identifier: NCT03178864." @default.
• W4386505453 created "2023-09-08" @default.
• W4386505453 creator A5000451439 @default.
• W4386505453 creator A5001397235 @default.
• W4386505453 creator A5001927403 @default.
• W4386505453 creator A5002006123 @default.
• W4386505453 creator A5002082628 @default.
• W4386505453 creator A5002127919 @default.
• W4386505453 creator A5002169144 @default.
• W4386505453 creator A5002837549 @default.
• W4386505453 creator A5004438676 @default.
• W4386505453 creator A5005293237 @default.
• W4386505453 creator A5005411055 @default.
• W4386505453 creator A5005557147 @default.
• W4386505453 creator A5007097196 @default.
• W4386505453 creator A5007303621 @default.
• W4386505453 creator A5009066790 @default.
• W4386505453 creator A5009393554 @default.
• W4386505453 creator A5009674088 @default.
• W4386505453 creator A5010355971 @default.
• W4386505453 creator A5010558193 @default.
• W4386505453 creator A5010855646 @default.
• W4386505453 creator A5011776784 @default.
• W4386505453 creator A5011832099 @default.
• W4386505453 creator A5012406960 @default.
• W4386505453 creator A5012790405 @default.
• W4386505453 creator A5012894644 @default.
• W4386505453 creator A5012917061 @default.
• W4386505453 creator A5013095123 @default.
• W4386505453 creator A5014072833 @default.
• W4386505453 creator A5014497964 @default.
• W4386505453 creator A5014742597 @default.
• W4386505453 creator A5016124763 @default.
• W4386505453 creator A5016204170 @default.
• W4386505453 creator A5016249935 @default.
• W4386505453 creator A5017983699 @default.
• W4386505453 creator A5018084260 @default.
• W4386505453 creator A5018372363 @default.
• W4386505453 creator A5018438042 @default.
• W4386505453 creator A5020373936 @default.
• W4386505453 creator A5020605085 @default.
• W4386505453 creator A5020646322 @default.
• W4386505453 creator A5020761707 @default.
• W4386505453 creator A5021008461 @default.
• W4386505453 creator A5021336555 @default.
• W4386505453 creator A5021786543 @default.
• W4386505453 creator A5022381205 @default.
• W4386505453 creator A5023034035 @default.
• W4386505453 creator A5023121746 @default.
• W4386505453 creator A5023506411 @default.
• W4386505453 creator A5023921810 @default.
• W4386505453 creator A5024028015 @default.
• W4386505453 creator A5024431722 @default.
• W4386505453 creator A5024508497 @default.
• W4386505453 creator A5024546274 @default.
• W4386505453 creator A5024741363 @default.
• W4386505453 creator A5024858377 @default.
• W4386505453 creator A5025115314 @default.
• W4386505453 creator A5027256157 @default.
• W4386505453 creator A5027568070 @default.
• W4386505453 creator A5029202028 @default.
• W4386505453 creator A5029549143 @default.
• W4386505453 creator A5030126622 @default.
• W4386505453 creator A5030849116 @default.
• W4386505453 creator A5032617287 @default.
• W4386505453 creator A5033065654 @default.
• W4386505453 creator A5033373289 @default.
• W4386505453 creator A5034531904 @default.
• W4386505453 creator A5034786036 @default.
• W4386505453 creator A5036054128 @default.
• W4386505453 creator A5038013330 @default.
• W4386505453 creator A5038022424 @default.
• W4386505453 creator A5038357434 @default.
• W4386505453 creator A5038515639 @default.
• W4386505453 creator A5039009237 @default.
• W4386505453 creator A5039265606 @default.
• W4386505453 creator A5039432888 @default.
• W4386505453 creator A5039632977 @default.
• W4386505453 creator A5040448750 @default.
• W4386505453 creator A5040579278 @default.
• W4386505453 creator A5040792880 @default.
• W4386505453 creator A5040854839 @default.
• W4386505453 creator A5041111413 @default.
• W4386505453 creator A5041498506 @default.
• W4386505453 creator A5042805957 @default.
• W4386505453 creator A5043610670 @default.
• W4386505453 creator A5044042332 @default.
• W4386505453 creator A5044185516 @default.
• W4386505453 creator A5044371836 @default.
• W4386505453 creator A5044496179 @default.
• W4386505453 creator A5046302942 @default.
• W4386505453 creator A5046826861 @default.
• W4386505453 creator A5046836931 @default.
• W4386505453 creator A5048757776 @default.
• W4386505453 creator A5048985261 @default.
• W4386505453 creator A5049558076 @default.
• W4386505453 creator A5050205623 @default.
• W4386505453 creator A5050583996 @default.
• W4386505453 creator A5050811879 @default.
• W4386505453 creator A5051555658 @default.

• next